Treatment, Management, and Prevention
At a Glance
Existing vascular dementia damage is usually permanent, but treatment can protect brain function and sometimes stabilize symptoms. Controlling blood pressure, diabetes, cholesterol, smoking, sleep, and stroke risk, along with exercise and rehabilitation, may help prevent further decline.
Treatment for vascular dementia is different from many other medical conditions because the primary goal is not to “cure” the damage that has already occurred. Instead, the focus is on protecting the healthy parts of your brain that remain [1]. Because vascular dementia is driven by blood vessel health, management is centered on stopping the “silent” strokes or chronic low blood flow that cause the disease to progress [1][2]. While established infarcts are generally permanent, symptoms and function can sometimes improve, stabilize, or fluctuate with comprehensive care.
Protecting the Brain: Managing Risk Factors
The most powerful tool for managing vascular dementia is optimizing vascular risk factors with your clinician. Research shows that managing these factors is an important way to prevent further strokes and vascular injury [3]. Treatment must be individualized, considering age, kidney disease, orthostatic symptoms (dizziness when standing), and fall risk. Do not change medication doses independently.
- Blood Pressure: High blood pressure (hypertension) is the leading driver of vascular brain damage [1]. Keeping your blood pressure within target ranges helps prevent the small-vessel “wear and tear” that leads to dementia [4].
- Diabetes and Cholesterol: High blood sugar and high cholesterol can both damage the lining of your blood vessels. While medication for these issues hasn’t been shown to “reverse” dementia, it is essential for preventing new strokes [2][5].
- Physical Activity and Rehabilitation: Regular exercise is one of the few interventions that may improve both physical function and thinking in people with vascular impairment [6]. Physical, occupational, and speech therapy can provide critical compensatory strategies.
- Lifestyle Habits: Quitting smoking, maintaining a healthy weight, and ensuring good sleep quality (including treating sleep apnea) are all critical for long-term brain protection [2][5].
Secondary Prevention: Aspirin and Blood Thinners
If you have already had a stroke or a “mini-stroke” (TIA), your doctor may prescribe antiplatelet medications (like aspirin, commonly used for many non-cardioembolic ischemic strokes) or anticoagulants (blood thinners, used for specific cardioembolic sources like atrial fibrillation) [7]. These are used for secondary prevention—meaning they are meant to prevent a second event [8]. These medications are not interchangeable. Never start, stop, or change these without consulting your prescribing clinician.
However, these medications come with a trade-off. They can increase the risk of bleeding in the brain (hemorrhage), especially if you have a condition called Cerebral Amyloid Angiopathy (CAA), where blood vessels are already fragile, or microbleeds, where careful specialist assessment is needed rather than an automatic prohibition [9]. Your doctor will balance your risk of a stroke against your risk of bleeding when deciding on these treatments [10].
The Role of Memory Medications
You may be familiar with drugs like donepezil (Aricept) or memantine (Namenda), which are commonly used for Alzheimer’s. In vascular dementia, their role is more limited and often inconsistent [5][11].
- Effectiveness: These drugs may offer a small, modest improvement in thinking for some people, particularly if “mixed dementia” (a combination of vascular and Alzheimer’s) is suspected [12][13]. They do not stop the underlying blood vessel disease [13].
- Side Effects: These medications can cause side effects. Cholinesterase inhibitors like donepezil can cause gastrointestinal issues (like nausea or diarrhea), weight loss, and a slow heart rate that can lead to fainting (syncope). Memantine more commonly causes dizziness, headache, constipation, or confusion [12][14]. Because of these risks, your clinician can help you safely reassess and potentially taper the medication if there is a lack of meaningful benefit [14].
Managing Mood and Behavior
It is very common for vascular dementia to cause changes in mood, such as depression, or behavioral issues like agitation [15][5].
- Non-Drug First: The first line of defense should always be “non-pharmacological” interventions. This includes creating a calm environment, simplifying daily routines, and using person-centered activities, caregiver education, and checking for hidden problems like pain, infection, or medication side effects to reduce apathy and distress [5][16].
- Medications: Antidepressants (specifically SSRIs) may be helpful if your symptoms followed a major stroke, and may be considered after an individualized risk-benefit review, taking care to monitor for risks like low sodium or falls [17][5]. Antipsychotics are considered a last resort; they carry significant risks, including an increased risk of stroke and death in people with dementia, and their use should be closely monitored and reviewed frequently with attempts to taper [18][19].
Common questions in this guide
Can vascular dementia damage be reversed?
What treatments can slow the progression of vascular dementia?
Should I take aspirin or a blood thinner for vascular dementia?
Do donepezil or memantine help people with vascular dementia?
How can depression or agitation be managed in vascular dementia?
What lifestyle changes can protect the brain with vascular dementia?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Which of my vascular risk factors—like blood pressure or cholesterol—are the most critical to manage right now?
- 2.Since my brain damage can't be reversed, what specific steps can we take to stop new damage from occurring?
- 3.If you're recommending aspirin or a blood thinner, how does that balance against my risk of brain bleeding?
- 4.Given my specific symptoms, do you think a trial of a drug like donepezil or memantine is worthwhile, or are the side effects too risky for me?
- 5.If I develop mood changes or agitation, what non-drug strategies can we try before turning to medications?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (19)
- 1
Canadian Stroke Best Practice Recommendations: Vascular cognitive impairment, 7th edition practice guidelines update, 2024.
Swartz RH, Longman RS, Lindsay MP, et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2025; (21(1)):e14324 doi:10.1002/alz.14324.
PMID: 39822128 - 2
ESO Guideline on covert cerebral small vessel disease.
Wardlaw JM, Debette S, Jokinen H, et al.
European stroke journal 2021; (6(2)):CXI-CLXII doi:10.1177/23969873211012132.
PMID: 34414301 - 3
Hypercholesterolaemia and vascular dementia.
Appleton JP, Scutt P, Sprigg N, Bath PM
Clinical science (London, England : 1979) 2017; (131(14)):1561-1578 doi:10.1042/CS20160382.
PMID: 28667059 - 4
Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment.
Smith EE, Barber P, Field TS, et al.
Alzheimer's & dementia (New York, N. Y.) 2020; (6(1)):e12056 doi:10.1002/trc2.12056.
PMID: 33209971 - 5
Current and Emerging Therapeutic Approaches for Vascular Cognitive Impairment and Dementia.
Goodall LS, Lennon MJ, Sachdev PS, et al.
Journal of the American College of Cardiology 2026; (87(1)):77-100 doi:10.1016/j.jacc.2025.09.1502.
PMID: 41498480 - 6
Effects of exercise on patients with vascular cognitive impairment based on ACSM recommendations: a systematic review of randomized controlled trials.
Ye Y, Wu K, Xu F, et al.
Journal of neurology 2024; (272(1)):31 doi:10.1007/s00415-024-12830-2.
PMID: 39666076 - 7
Small-vessel disease in the brain.
Singh A, Bonnell G, De Prey J, et al.
American heart journal plus : cardiology research and practice 2023; (27()):100277 doi:10.1016/j.ahjo.2023.100277.
PMID: 38511094 - 8
Antiplatelets and Vascular Dementia: A Systematic Review.
Alexander P, Visagan S, Jawhar S, et al.
Journal of aging research 2022; (2022()):9780067 doi:10.1155/2022/9780067.
PMID: 36245899 - 9
Updated imaging markers in cerebral amyloid angiopathy: What radiologists need to know.
Tanaka F, Maeda M, Kishi S, et al.
Japanese journal of radiology 2025; (43(5)):736-751 doi:10.1007/s11604-024-01720-2.
PMID: 39730931 - 10
A practical approach to the management of cerebral amyloid angiopathy.
Kozberg MG, Perosa V, Gurol ME, van Veluw SJ
International journal of stroke : official journal of the International Stroke Society 2021; (16(4)):356-369 doi:10.1177/1747493020974464.
PMID: 33252026 - 11
Pharmacotherapy for Vascular Cognitive Impairment.
Farooq MU, Min J, Goshgarian C, Gorelick PB
CNS drugs 2017; (31(9)):759-776 doi:10.1007/s40263-017-0459-3.
PMID: 28786085 - 12
Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
Battle CE, Abdul-Rahim AH, Shenkin SD, et al.
The Cochrane database of systematic reviews 2021; (2()):CD013306 doi:10.1002/14651858.CD013306.pub2.
PMID: 33704781 - 13
Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis.
Jin BR, Liu HY
Neural regeneration research 2019; (14(5)):805-816 doi:10.4103/1673-5374.249228.
PMID: 30688266 - 14
Efficacy of Cholinesterase Inhibitors in Vascular Dementia: An Updated Meta-Analysis.
Chen YD, Zhang J, Wang Y, et al.
European neurology 2016; (75(3-4)):132-41 doi:10.1159/000444253.
PMID: 26918649 - 15
Behavioral variations among vascular cognitive impairment subtypes - A comparative study.
Bhat A, Biswas A, Das G, et al.
Applied neuropsychology. Adult 2023; (30(4)):439-446 doi:10.1080/23279095.2021.1954002.
PMID: 34294015 - 16
Using dolls for therapeutic purposes: A study on nursing home residents with severe dementia.
Cantarella A, Borella E, Faggian S, et al.
International journal of geriatric psychiatry 2018; (33(7)):915-925 doi:10.1002/gps.4872.
PMID: 29671901 - 17
Considerations and Current Trends in the Management of the Geriatric Patient on a Consultation-Liaison Service.
Glass OM, Hermida AP, Hershenberg R, Schwartz AC
Current psychiatry reports 2020; (22(5)):21 doi:10.1007/s11920-020-01147-2.
PMID: 32285305 - 18
Dementia Prevention and Treatment: A Narrative Review.
Reuben DB, Kremen S, Maust DT
JAMA internal medicine 2024; (184(5)):563-572 doi:10.1001/jamainternmed.2023.8522.
PMID: 38436963 - 19
The Use of Antipsychotic Drugs for Treating Behavioral Symptoms in Alzheimer's Disease.
Calsolaro V, Antognoli R, Okoye C, Monzani F
Frontiers in pharmacology 2019; (10()):1465 doi:10.3389/fphar.2019.01465.
PMID: 31920655
This page is for informational purposes only and does not constitute medical advice about vascular dementia. Consult your clinician before changing medicines or making treatment or lifestyle decisions.
Get notified when new evidence is published on vascular dementia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.